External broker reports(aggregated public sources), CMB International

CMB International

External broker reports(aggregated public sources)

Incorporated in Hong Kong, supported by the mainland and targeting in global market, CMB International Capital Corporation Limited (“CMBI”) is an integrated financial institution providing comprehensive and professional services. As a wholly-owned subsidiary of China Merchants Bank ("CMB"), by leveraging on the Group’s synergy and coordination in domestic and overseas markets, as well as CMB’s strong resources and outstanding social reputation, CMBI and its subsidiaries have been actively implementing diversified business strategies and set up an overall layout of main business segments including Corporate Finance, Asset Management, Wealth Management, Global Markets and Structured Finance, etc. Adhering to the philosophy of “being clients oriented and increasing our own values by the way of creating value for clients”, CMBI endeavors to provide quality and integrated financial services to institutional, corporate and individual customers both domestic and overseas including Hong Kong IPO sponsorship and underwriting, share placement and rights issue for listed companies, financial advisors, bonds issuance services, asset management, direct investment, wealth management, equity sales and trading, etc.

Equity Bottom-Up

Innovent Biologics Inc / Equity Bottom-Up

<ul><li>Innovent has announced a global strategic partnership with Takeda on several key oncology assets, including IBI363 (PD-1/IL-2), IBI343 (CLDN18.2 ADC), and potentially IBI3001 (EGFR/B7H3 ADC).</li><li>This partnership is designed to expand Innovent’s global footprint, while strengthening Takeda's solid tumor pipeline.</li><li>Under the agreement, Takeda will lead global development of IBI363, with Innovent sharing 40% of the development costs. </li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Innovent has announced a global strategic partnership with Takeda on several key oncology assets, including IBI363 (PD-1/IL-2), IBI343 (CLDN18.2 ADC), and potentially IBI3001 (EGFR/B7H3 ADC).This partnership is designed to expand Innovent’s global footprint, while strengthening Takeda's solid tumor pipeline.Under the agreement, Takeda will lead global development of IBI363, with Innovent sharing 40% of the development costs. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Innovent Biologics (1801 HK) - Strategic Partnership with Takeda to Develop Global R&D ...

<ul><li>Innovent reported 1H25 revenue of RMB5.95bn (+51% YoY), with product sales of RMB5.23bn (+37% YoY), achieving 51% of our prior full-year forecasts and exceeding our expectations.</li><li>Sintilimab sales rose 15% YoY to US$275mn (per Eli Lilly), while new products—i.e. PCSK9 mAb and IGF-1R—drove product growth in 1H25.</li><li>Profitability improved materially in 1H25, with non-IFRS net profit reaching RMB1.21bn and EBITDA amounting to RMB1.41bn, compared to a loss in 1H24. </li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Innovent reported 1H25 revenue of RMB5.95bn (+51% YoY), with product sales of RMB5.23bn (+37% YoY), achieving 51% of our prior full-year forecasts and exceeding our expectations.Sintilimab sales rose 15% YoY to US$275mn (per Eli Lilly), while new products—i.e. PCSK9 mAb and IGF-1R—drove product growth in 1H25.Profitability improved materially in 1H25, with non-IFRS net profit reaching RMB1.21bn and EBITDA amounting to RMB1.41bn, compared to a loss in 1H24. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Innovent Biologics (1801 HK) - IBI363 Advancing Towards Global Development

<ul><li>BI363 positioned as a promising next-generation IO therapy with Ph3 trials underway.</li><li>Strong survival benefits and broad potential position IBI363 (PD-1/IL-2) as a potential blockbuster next-gen IO therapy—especially for IOresistant and cold tumors.</li><li>In sq-NSCLC, IBI363 (3mg/kg) achieved a highly competitive mPFS of 9.3 months, far exceeding docetaxel (3.9 months for sqand 3.6 months for nsq-NSCLC).</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

BI363 positioned as a promising next-generation IO therapy with Ph3 trials underway.Strong survival benefits and broad potential position IBI363 (PD-1/IL-2) as a potential blockbuster next-gen IO therapy—especially for IOresistant and cold tumors.In sq-NSCLC, IBI363 (3mg/kg) achieved a highly competitive mPFS of 9.3 months, far exceeding docetaxel (3.9 months for sqand 3.6 months for nsq-NSCLC).Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Innovent Biologics (1801 HK) - Advancing a Broad Pipeline of Next-Generation Therapies

Thematic (Sector/Industry)

<ul><li>Innovent: ASCO data reinforce IBI363’s potential as a potential nextgeneration IO.</li><li>We view IBI363 as a highly promising candidate in the IOresistant sq-NSCLC space, supported by an impressive mPFS of 7.3 months in monotherapy, which is very competitive compared to other innovative agents. Innovent plans to initiate a Ph3 trial of IBI363 in IOresistant sq-NSCLC in 2H25. In 3L+ CRC, IBI363 has shown superior early efficacy signals and a more favorable safety profile.</li><li>IBI363 mono delivered an ORR of 12.7% and an mOS of 16.1 months—both significantly outperforming fruquintinib. </li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Innovent: ASCO data reinforce IBI363’s potential as a potential nextgeneration IO.We view IBI363 as a highly promising candidate in the IOresistant sq-NSCLC space, supported by an impressive mPFS of 7.3 months in monotherapy, which is very competitive compared to other innovative agents. Innovent plans to initiate a Ph3 trial of IBI363 in IOresistant sq-NSCLC in 2H25. In 3L+ CRC, IBI363 has shown superior early efficacy signals and a more favorable safety profile.IBI363 mono delivered an ORR of 12.7% and an mOS of 16.1 months—both significantly outperforming fruquintinib. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Healthcare - ASCO Highlights: Spotlight on Next-Gen IO & ADCs

<ul><li>To cancel the related-party transaction to protect the interests of investors.</li><li>Innovent previously announced its wholly-owned subsidiary Fortvita would sell 20.39% of shares for a transaction price of US$20.5mn, with the subscribing party being Lostrancos.</li><li>Dr. Yu Dechao, the Chairman and Executive Director, will hold 82.93% of Lostrancos. </li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

To cancel the related-party transaction to protect the interests of investors.Innovent previously announced its wholly-owned subsidiary Fortvita would sell 20.39% of shares for a transaction price of US$20.5mn, with the subscribing party being Lostrancos.Dr. Yu Dechao, the Chairman and Executive Director, will hold 82.93% of Lostrancos. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Innovent Biologics (1801 HK) - Strong fundamentals enriched by a wealth of R&D catalysts

China

Innovent Biologics, Inc. operates as a biopharmaceutical company. The Company develops, manufactures, and distributes monoclonal antibody drug candidates for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and other diseases. Innovent Biologics serves customers in China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Innovent Biologics Inc (1801 HK)

Innovent Biologics (1801 HK) - Strategic Partnership with Takeda to Develop Global R&D ...

Innovent has announced a global strategic partnership with Takeda on several key oncology assets, including IBI363 (PD-1/IL-2), IBI343 (CLDN18.2...

CMB International

Innovent Biologics (1801 HK) - IBI363 Advancing Towards Global Development

Innovent reported 1H25 revenue of RMB5.95bn (+51% YoY), with product sales of RMB5.23bn (+37% YoY), achieving 51% of our prior full-year forecasts...

CMB International

Innovent Biologics (1801 HK) - Advancing a Broad Pipeline of Next-Generation Therapies

Strong survival benefits and broad potential position IBI363 (PD-1/IL-2) as a potential blockbuster next-gen IO therapy—especially for IOresistant...

CMB International

Healthcare - ASCO Highlights: Spotlight on Next-Gen IO & ADCs

Innovent: ASCO data reinforce IBI363’s potential as a potential nextgeneration IO. We view IBI363 as a highly promising candidate in the...

CMB International

Innovent Biologics (1801 HK) - Strong fundamentals enriched by a wealth of R&D catalysts

Innovent previously announced its wholly-owned subsidiary Fortvita would sell 20.39% of shares for a transaction price of US$20.5mn, with the...

CMB International

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)